Dr. Rodriguez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2520 Elisha Avenue
Zion, IL 60099Phone+1 847-748-0627
Summary
- Dr. Tulio Rodriguez is a hematologist/oncologist who specializes on hematologic malignancies and bone marrow transplantation. He completed his training in Hematology/Oncology and Bone Marrow Transplantation at the University of Texas Health Science Center in San Antonio, Texas. He has held faculty appointments at Texas A&M Health Science Center, RUSH University School of Medicine, and became Professor of Medicine at Loyola University Stritch School of Medicine in Illinois where he practiced for 14 years. He is currently a Professor of Medicine at Rosalind Franklin University of Medicine and Science in North Chicago, IL.
Dr. Rodriguez has published and lectured widely on a range of medical and bone marrow transplant topics. He has devoted much of his research career to the study of hematologic malignancies and hematopoietic stem cell transplantation. He is a member of the Center for International Blood and Marrow Transplant Research and is an advocate for National Institutes of Health research funding through the American Society of Hematology Advocacy Leadership Institute.
Dr. Rodriguez is board certified in Hematology by the American Board of Internal Medicine Subspecialty and is currently the Director of Hematology, Bone Marrow Transplant and Cellular Therapy Program at City of Hope Chicago.
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1993 - 1996
- VA Caribbean Healthcare SystemResidency, Internal Medicine, 1990 - 1993
- Pontificia Universidad Católica Madre y MaestraClass of 1987
Certifications & Licensure
- IL State Medical License 2000 - 2026
- TX State Medical License 1996 - 2025
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2009 Jan 01
- S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- 3 citationsBusulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term ...Patrick Hagen, Anita D'Souza, Parameswaran Hari, Omar Davila, Mei-Jie Zhang
Leukemia & Lymphoma. 2020-08-31 - 7 citationsWhen Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.Brendan A. Gilmore, Roger A. Rodby, David Cimbaluk, Parameswaran Venugopal, Pritesh R. Patel
Clinical Lymphoma, Myeloma & Leukemia. 2019-06-01 - 28 citationsBusulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaTulio E. Rodriguez, Parameswaran Hari, Patrick J. Stiff, Scott E. Smith, Danielle Sterrenberg
Biology of Blood and Marrow Transplantation. 2016-08-01
Press Mentions
- Adding Isatuximab to Standard Backbone Prolongs PFS in MyelomaJune 14th, 2024
- Advocate Lutheran General to Host Marrow Registry DriveNovember 12th, 2018
- On the Holiday to Give Thanks, 20-Year-Old Marcela Received a Cancer DiagnosisAugust 20th, 2018
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: